|
EMA Biosimilars Q&A Aims to Clarify Presubmission Issues, Review Timelines
The European Medicines Agency (EMA) has published a question-and-answer guideline on marketing applications for biosimilars, providing advice on a number of presubmission issues, such as requesting an accelerated assessment, and giving detailed answers about review timing.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives